Salvagno Gian Luca, Lippi Giuseppe
Section of Clinical Biochemistry, University of Verona, 37126 Verona, Italy.
Vaccines (Basel). 2022 Jun 2;10(6):890. doi: 10.3390/vaccines10060890.
Objective: In this work we monitored both total and IgG anti-SARS-CoV-2 antibodies responses after BNT162b2 vaccine booster immunization in a cohort of ostensibly healthy healthcare workers. Methods: The study population consisted of 266 subjects (median age, 46 years and interquartile range (IQR), 35−52 years; 168 females) undergoing homologous 30-µg BNT162b2 booster administration. Serum samples were collected immediately before the booster dose and 1 month after. Results: The concentration of anti-SARS-CoV-2 RBD total antibodies and anti-SARS-CoV-2 spike trimeric IgG increased by 31 (IQR, 16−53) and 22 (IQR, 11−43) folds, respectively, after receiving the BNT162b2 vaccine booster. A highly significant Spearman′s correlation was found between the relative increase (i.e., ratio of post-booster and pre-booster serum values) of anti-SARS-CoV-2 RBD total antibodies and anti-SARS-CoV-2 spike trimeric IgG (r = 0.86; p < 0.001). Conclusion: These results suggest that monitoring of post-BNT162b2 booster immunization for purposes of identifying “low responders” could be conducted almost interchangeably with either total or IgG anti-SARS-CoV-2 antibodies.
在这项研究中,我们监测了一组表面健康的医护人员接种BNT162b2疫苗加强针后的抗SARS-CoV-2总抗体和IgG抗体反应。方法:研究人群包括266名受试者(中位年龄46岁,四分位间距(IQR)为35 - 52岁;168名女性),接受30μg BNT162b2同源加强针接种。在加强针接种前即刻和接种后1个月采集血清样本。结果:接种BNT162b2疫苗加强针后,抗SARS-CoV-2 RBD总抗体和抗SARS-CoV-2刺突三聚体IgG的浓度分别增加了31倍(IQR为16 - 53)和22倍(IQR为11 - 43)。抗SARS-CoV-2 RBD总抗体和抗SARS-CoV-2刺突三聚体IgG的相对增加量(即加强针后与加强针前血清值的比值)之间存在高度显著的Spearman相关性(r = 0.86;p < 0.001)。结论:这些结果表明,为识别“低反应者”而对BNT162b2疫苗加强针接种后进行监测时,使用抗SARS-CoV-2总抗体或IgG抗体几乎可以相互替代。